g(m1)-ganglioside and siagoside

Topics: Antibodies; Autoradiography; Benzazepines; Cholera Toxin; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; G(M1) Ganglioside; Glial Fibrillary Acidic Protein; Ischemic Attack, Transient; Nerve Tissue Proteins; Ornithine Decarboxylase; Phosphoproteins; Phosphorylation; Putrescine; Receptors, Dopamine; Receptors, Neurotransmitter; Reperfusion; Substantia Nigra; Synaptic Transmission; Tyrosine 3-Monooxygenase

Randomized, double-blind, sequential, multicenter clinical trial of two doses of Sygen versus placebo.. To determine efficacy and safety of Sygen in acute spinal cord injury.. An earlier, single-center trial in 28 patients showed an improvement (50.0% vs. 7.1%, P = 0.034) in marked recovery with Sygen.. Standard clinical trial techniques.. The prospectively planned analysis at the prespecified endpoint time for all patients was negative. There was a significant effect in all patients in the primary outcome variable (the percentage of marked recovery) at week 8, the end of the dosing period. There was a significant effect in all patients in the time at which marked recovery is first achieved. Restricted to severity Group B, which has small sample size, the primary efficacy analysis showed a trend but did not reach significance. There is a large, consistent and, at some time points, significant effect in the primary outcome variable in the nonoperated patients through week 26. The American Spinal Injury Association motor, light touch, and pinprick scores showed a consistent trend in favor of Sygen, as also did bowel function, bladder function, sacral sensation, and anal contraction. The less severely injured patients appeared to have a greater beneficial drug effect. Evidence against an effect of Sygen was minimal and scattered.. Although not proven in the primary efficacy analysis of this trial, Sygen appears to be beneficial in patients with severe spinal cord injury.

Topics: Acute Disease; Adolescent; Adult; Aged; Double-Blind Method; Female; G(M1) Ganglioside; Humans; Logistic Models; Male; Middle Aged; Neuroprotective Agents; Prospective Studies; Recovery of Function; Spinal Cord Injuries; Treatment Outcome

Post hoc secondary analysis of data from 1992 to 1998 in the trial of Sygen in Acute Spinal Cord Injury.. Quasi-epidemiologic understanding of injury and treatment patterns and of recruitment in an SCI trial. No drug efficacy results.. The most recent large epidemiologic study was the National SCI Database by Stover and colleagues around 1980.. Emphasis on descriptive, rather than inferential, statistics: consistent with secondary analysis.. The study involved 760 patients at 28 centers in North America. Cervical injuries were more common than thoracic, and complete injuries were more common than incomplete injuries. Recruitment in the complete cervical stratum was 332, but the incomplete thoracic strata had only 31 patients combined. Vital signs at arrival and on randomization show fair stability. Clock times show more injuries on weekends and nights but suggest immediate attention was given. Elapsed times to treatment (especially EMT and Medevac arrival) are short. The rate of direct admission to tertiary centers, traction weight, and time to surgery vary among centers. Inpatient rehabilitation appeared driven by insurance in addition to severity.. The imbalances in favor of cervical and of complete injuries would make it hard for studies to attain results for SCI in general. The vital signs and time patterns suggest local protocol-driven stabilization to prevent secondary physiologic injury early after SCI. Some features of care vary among centers, but the sparseness of prospective data in specific injury and treatment categories suggests that treatment guidelines have limited empirical support and should be made cautiously.

Topics: Acute Disease; Adolescent; Adult; Aged; Decompression, Surgical; Female; G(M1) Ganglioside; Humans; Male; Middle Aged; Neuroprotective Agents; North America; Patient Selection; Randomized Controlled Trials as Topic; Retrospective Studies; Spinal Cord Injuries; Time Factors

Post hoc, secondary analysis of data from 1992 to 1998 in the trial of Sygen in acute spinal cord injury.. Quasi-epidemiologic understanding of measurement tools and of recovery patterns. No drug efficacy results.. Many authors have studied individual scales for measuring the severity of spinal cord injury.. Emphasis on descriptive, rather than inferential, statistics: consistent with secondary analysis.. Of the 760 patients, 43 died within 365 days. The rate was higher for complete injuries (7.1% vs. 3.2%, P = 0.017). Marked recovery at 26 weeks was more frequent in those with better baseline American Spinal Injury Association (ASIA) Impairment Scale (AIS) scores, but was not different for methylprednisolone within versus after 3 hours. Light touch scores improved at each visit, more so in those with higher scores at baseline. Bladder control similarly improved. Motor and sensory scores exhibited departures from assumptions underlying normal-theory statistical techniques: t test and analysis of variance. Furthermore, they were mixtures of differing distributions from different study strata, so that overall conclusions depend on the mixture of patients seen.. The prognosis of these patients with spinal cord injury seen at 28 centers in North America during the mid-1990s appears better than was often assumed earlier. The general patterns are similar across different measurement scales, although there are intriguing differences. The patterns in different strata are different in specifics, and complete injuries do less well. Pooling data from different strata may result in probability distributions that depart from normal-theory assumptions and give misleading results depending on recruitment patterns.

Topics: Adolescent; Adult; Aged; Female; G(M1) Ganglioside; Humans; Male; Middle Aged; Neuroprotective Agents; North America; Prognosis; Randomized Controlled Trials as Topic; Recovery of Function; Retrospective Studies; Severity of Illness Index; Spinal Cord Injuries

Topics: Acute Disease; G(M1) Ganglioside; Humans; Multicenter Studies as Topic; Neuroprotective Agents; Randomized Controlled Trials as Topic; Spinal Cord Injuries; Treatment Outcome

Topics: Acute Disease; Animals; Antiparkinson Agents; Brain Ischemia; Drugs, Investigational; G(M1) Ganglioside; Humans; Neuroprotective Agents; Parkinson Disease; Stroke

The time course for the ischemia-induced changes in the subcellular distribution of protein kinase C (PKC) (alpha), (beta II), and (gamma) and the activity of PKC were studied in the neocortex of rats subjected to 1, 2, 3, 5, 10, and 15 min of global cerebral ischemia. In the particulate fraction, a 14-fold increase in PKC (gamma) levels was seen at 3 min of ischemia, which further increased at 5-15 min of ischemia. At 15 min of ischemia, PKC (alpha) and (beta II) levels had increased two- and six-fold, respectively. In the cytosolic fraction, a transient early 1.4-fold increase in PKC (beta II) and PKC (gamma) levels was seen, whereas no change in the levels PKC (alpha) was noted. PKC (gamma) levels then progressively declined, reaching 50% at 15 min of ischemia. At 5 min of ischemia, a 43% decrease in PKC activity was seen in the particulate fraction, reaching 50% at 15 min of ischemia concomitant with a 27% decrease in the cytosolic fraction. There was no change in the activator-independent PKC activity. Pretreatment with the ganglioside AGF2 prevented the redistribution of PKC (gamma) in the particulate fraction at 5 min, but not at 10 min of ischemia. The observed time course for the translocation of PKC (gamma) parallels the ischemia-induced release of neurotransmitters and increased levels of diacylglycerols, arachidonate, and increased levels of diacylglycerols, arachidonate, and intracellular calcium and delineates this subspecies as especially ischemia-sensitive. Ganglioside pretreatment delayed the translocation of PKC (gamma), possibly by counter-acting the effects of ischemia-induced factors that favor PKC binding to cell membranes.

Topics: Animals; Biological Transport; Brain Ischemia; G(M1) Ganglioside; Isoenzymes; Male; Protein Kinase C; Rats; Rats, Wistar; Subcellular Fractions; Time Factors

These experiments tested the effectiveness of parenterally administered gangliosides and amphetamine as treatments for spatial learning deficits caused by bilateral lesions of the neostriatum. In Expt. 1, rats were tested postsurgically for 30 days on a shock-avoidance, spatial reversal task. Treatments of gangliosides (GM1 at 30 mg/kg, and AGF2 at 20 mg/kg and 30 mg/kg) and D-amphetamine (2 mg/kg) significantly decreased lesion-induced learning deficits on this task, while treatments of 10 mg/kg AGF2 and the combination of GM1 (30 mg/kg) and D-amphetamine (2 mg/kg) were ineffective. In Expt. 2, rats were given bilateral neostriatal lesions and treated with GM1 (30 mg/kg), AGF2 (20 mg/kg) or D-amphetamine (2 mg/kg) and tested postsurgically for 5 days on a place learning task in the Morris water maze. Only the GM1-treated rats showed a reduction in lesion-induced place learning deficits on this task. Since in both experiments, cell counts near the area of the lesion revealed no differences among any of the brain-damaged groups, it was suggested that the treatments exert their behavioral effects by biochemically activating spared neurons, independent of any ultimate effects they may have on neuronal survival.

Topics: Adenosine Monophosphate; Animals; Brain Mapping; Cell Count; Dextroamphetamine; Discrimination Learning; Electroshock; G(M1) Ganglioside; Injections, Intraperitoneal; Male; Neostriatum; Neuroglia; Neurons; Orientation; Rats; Rats, Sprague-Dawley; Reversal Learning; Sensory Thresholds

Hemitransection of the nigro-striatal bundle in adult rats reduced [3H]dopamine ([3H]DA) uptake into striatal slices from the lesioned side to about 20% of that in the contralateral side 5 days after surgery. Spontaneous recovery of [3H]DA uptake was observed at days 8 and 15 post-lesion (42 and 67% of the unoperated side, respectively). After a short treatment (3 days) with the GM1 ganglioside inner ester (AGF2, 30 mg/kg i.p., daily, starting on day 2 after surgery) [3H]DA uptake amounted to 52% of that in the unoperated side. The electrically evoked fractional overflow of [3H]DA was increased by 500% in slices prepared from the lesioned side 5 days after injury, largely due to the reduced re-uptake by the DA axon terminals. The increase on day 5 was only about 350% in AGF2-treated animals. The DA D2 receptor antagonist, (-)-sulpiride, potentiated the stimulus-evoked overflow of [14C]acetylcholine in slices from the unoperated side prelabelled with [14C]choline. The effect of (-)-sulpiride was much reduced (by about 80%) in the lesioned striata at days 5 and 8 after surgery. Partial recovery was seen at day 15. The lesion did not modify the (-)-sulpiride effect in animals treated with AGF2 from the 2nd to the 5th day post-lesion. Thus early ganglioside administration slows the loss of endogenous dopaminergic control of acetylcholine release caused by partial hemitransection of the nigro-striatal bundle.

Topics: Acetylcholine; Animals; Corpus Striatum; Dopamine; G(M1) Ganglioside; Male; Rats; Rats, Inbred Strains; Sulpiride

Transient forebrain ischemia induced in rats by the four-vessel occlusion method is known to produce severe neural damage in the hippocampus and striatum and a behavioral syndrome the major symptom of which is a working memory deficit. Recent evidence suggests that monosialogangliosides can ameliorate postischemic symptoms. Our purpose was to study the effect of siagoside, the inner ester of GM1 ganglioside, on some behavioral and morphological impairments induced by four-vessel occlusion in rats.. Rats were injected daily with 5 mg/kg i.p. siagoside starting 4 hours after the cerebral ischemia. After 14 days the rats were tested for working memory in a water T maze or scored for apomorphine-induced stereotypy. The rats were killed 21 days after the cerebral ischemia. Histological and computer-assisted morphometric analyses were performed on cresyl violet-stained brain sections, which were graded according to a neuropathologic score, and on sections stained with a monoclonal antiserum against dopamine and cyclic adenosine-3',5'-monophosphate-regulated phosphoprotein, a marker for striatal dopaminoceptive neurons.. Siagoside treatment reduced the stereotypy score induced by low doses of apomorphine and the extent of striatal lesions but did not affect the working memory deficit or the extent of hippocampal lesions.. Daily siagoside treatment after acute cerebral ischemia attenuates some morphological and functional deficits related to striatal damage. These effects can be interpreted as a selective protective action on striatal neural populations or as a modulatory action on neural systems involved in striatal control. These data are consistent with preliminary clinical reports showing that monosialogangliosides enhance motor recovery after acute ischemic stroke.

Topics: Animals; Apomorphine; Behavior, Animal; Brain; Brain Ischemia; Choice Behavior; Corpus Striatum; Dopamine and cAMP-Regulated Phosphoprotein 32; G(M1) Ganglioside; Germ-Free Life; Hippocampus; Male; Memory Disorders; Nerve Tissue Proteins; Phosphoproteins; Prosencephalon; Rats; Rats, Inbred Strains; Stereotyped Behavior

Ganglioside AGF2 prevented the cognitive and locomotor alterations induced by intraventricular colchicine. Adult male rats were initially trained to perform a standard radial arm maze (RAM) task. Following training, they were injected intraperitoneally with 10 mg/kg AGF2 (COL/AGF2), cerebrospinal fluid (CSF/AGF2) or the saline vehicle (COL/SAL, CSF/SAL) for 3 days prior to and for 14 days following the bilateral injection of colchicine (7 micrograms/0.5 microliters) or artificial CSF into the lateral ventricles. Colchicine (COL/SAL) impaired performance of the standard RAM task as well as a working memory version of the task in which various delays were imposed between the fourth and fifth arm choices. Colchicine also produced a transient hyperactivity which subsided within 10 weeks following surgery. In contrast, AGF2 (COL/AGF2) prevented the impairments in RAM performance and the alterations in locomotor behavior. Colchicine also produced significant decreases in hippocampal ChAT activity and high affinity choline uptake that were prevented by prior treatment with AGF2. Finally, colchicine produced a 35% decrease in the number of acetylcholinesterase-positive (cholinergic) neurons in the medial septum and vertical limb of the diagonal band (MS/VLDB) which was also prevented by AGF2. Thus, the behavioral and neurochemical protection afforded by AGF2 was paralleled by a prevention of the loss of hippocampal cholinergic parameters and cholinergic neurons in the MS/VLDB.

Topics: Animals; Behavior, Animal; Cell Survival; Choline O-Acetyltransferase; Colchicine; G(M1) Ganglioside; Injections, Intraventricular; Locomotion; Male; Memory Disorders; Rats

Ganglioside AGF2 attenuated both the cognitive impairments and the cholinergic hypofunction induced by ethylcholine aziridinium ion (AF64A). Adult male rats were initially trained to perform a standard radial arm maze (RAM) task. Following training, they were injected intraperitoneally with 10 mg/kg AGF2 (AF/AGF2, CSF/AGF2) or the saline vehicle (AF/SAL, CSF/SAL) for 3 days prior to and for 14 days following bilateral injection of AF64A (3 nmol/side) or artificial CSF into the lateral ventricles. AF64A (AF/SAL) impaired performance of the standard RAM task and a working memory version of the task in which various delays were imposed between the fourth and fifth arm choices. In contrast, animals that received AGF2 and AF64A (AF/AGF2) were initially impaired on the standard RAM task but rapidly recovered and were performing as well as the control groups (CSF/SAL, CSF/AGF2) by the end of training. The AF/AGF2 group, however, exhibited persistent deficits on the working memory version of the RAM task. These data demonstrate that AGF2 promotes behavioral recovery in a task-dependent manner in this model system. Neurochemical analysis revealed that AF64A produced a significant 37% decrease in hippocampal ChAT activity that was significantly attenuated, but not prevented, by prior treatment with AGF2. Thus the behavioral recovery afforded by AGF2 might be related to increased cholinergic activity in the hippocampus that is sufficient for the performance of tasks which either lack or have a minimal working memory component. An analysis of the temporal profile of AGF2-induced neurochemical recovery revealed that ChAT activity was enhanced at 20, but not 2 or 11, weeks following AF64A. Since AGF2 did not attenuate the cholinergic cell loss (35%) induced by AF64A in the medial septum these data indicate that AGF2 might have (1) enhanced sprouting of cholinergic terminals following the initial insult, (2) directly increased ChAT activity in surviving neurons, or (3) induced behavioral and neurochemical recovery through a combination of these or other mechanisms.

Topics: Acetylcholinesterase; Animals; Aziridines; Cerebral Ventricles; Choline; Choline O-Acetyltransferase; G(M1) Ganglioside; Hippocampus; Injections, Intraventricular; Learning; Male; Memory; Neuromuscular Blocking Agents; Rats; Rats, Inbred Strains; Reference Values; Space Perception

We assessed the consequences of transitory global cerebral ischemia and the influence of monosialoganglioside inner ester (AGF 2) treatment on neurologic outcome, cerebral blood flow, and cerebral metabolic rate in monkeys over 48 hours. Global cerebral ischemia was produced by a cervical tourniquet and a lowering of blood pressure to 6.65 kPa; recirculation followed after 30 minutes. AGF 2 (30 mg/kg) was administered intravenously immediately after initiation of recirculation and intramuscularly twice a day for 48 hours. Our results show that treatment with AGF 2 significantly accelerated the rate of neurologic recovery. Improvement was evident 5 hours after ischemia; full neurologic recovery was observed in half of the monkeys 48 hours after ischemia. This recovery was associated with a less severe reduction in cerebral blood flow without a concomitant increase in the cerebral metabolic rate.

Topics: Animals; Blood Glucose; Brain; Cerebrovascular Circulation; Coma; Female; G(M1) Ganglioside; Ischemic Attack, Transient; Macaca fascicularis; Male; Random Allocation

Bilateral injection of 3.5 micrograms of colchicine into the dentate gyrus produced specific learning and memory impairments together with a selective pattern of neuropathology. Animals injected with colchicine exhibited a significant impairment in their ability to perform the working memory, but not the reference memory, component of a multiple component T-maze task. These deficits were transient and over time all animals were able to reaquire the task to preoperative levels of performance. Histological analyses revealed that intradentate injection of colchicine produced 1) a significant decrease in the width of both the superior and inferior blades of the dentate gyrus reflecting the extensive loss of granule cells, 2) a related decrease in the size of the dentate molecular layer, and 3) a decrease in the number of cholinergic neurons in the medial septum. The second phase of the experiment demonstrated that gangliosides GM1 and AGF2 did not prevent the initial impairments in working memory performance induced by colchicine but rather accelerated the rate at which it recovered. The gangliosides did not decrease the extent of neuronal damage; there was no sparing of granule cells in the dentate gyrus or cholinergic neurons in the medial septum. These data further support a role for the hippocampus in working memory processes and they also indicate that gangliosides GM1 and AGF2 might be useful for treating the behavioral deficits induced by hippocampal damage.

Topics: Animals; Colchicine; Discrimination Learning; G(M1) Ganglioside; Hippocampus; Injections; Male; Memory; Mental Recall; Nerve Regeneration; Orientation; Rats; Rats, Inbred Strains; Retention, Psychology

Topics: 6-Ketoprostaglandin F1 alpha; Animals; Arachidonic Acids; Brain; Brain Ischemia; Cell Membrane Permeability; G(M1) Ganglioside; Lactates; Male; Rats; Rats, Inbred Strains; Reperfusion; Thromboxane B2